Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 1FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 1

Conditions

Peripheral Nervous System Diseases 1Ototoxicity 1Breast Neoplasms 1

Interventions

Cyclophosphamide 641Bevacizumab 552Paclitaxel 534Carboplatin 533Cisplatin 480pembrolizumab 456Gemcitabine 422Docetaxel 415Rituximab 386Radiotherapy 373Dexamethasone 351Doxorubicin 330Nivolumab 308Fluorouracil 286Capecitabine 260Etoposide 245Prednisone 244Oxaliplatin 242Erlotinib Hydrochloride 242Cytarabine 233Lenalidomide 232Trastuzumab 226Pemetrexed 220Vincristine 212fludarabine phosphate 208Leucovorin 208Cetuximab 208Filgrastim 204Bortezomib 193Methotrexate 183

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Has results × Thioctic Acid × Clear all
NCT01313117 2014-10-02

Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Neuropathy

Northwestern University

Phase 1/2 Completed
9 enrolled 7 charts
Breast

Breast Neoplasms, Peripheral Nervous System Diseases

NCT00477607 2014-03-07

Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin

VA Office of Research and Development

Phase 2/3 Completed
39 enrolled 11 charts

Ototoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡